Regencell Bioscience Holding (NASDAQ:RGC) shares have rallied over 72,500% in the past year despite recording losses of £3.2 million ($4.4 million) in the fiscal year ended June 30, 2024. The Hong Kong-based traditional Chinese medicine company sells herbal medicine treatments for neurocognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD).
The unstoppable rally drove chief executive officer Yat-Gai Au's 86% stake in the company to a value of £1.9 billion ($25.6 billion), placing him on the list of the world's 100 richest.
